

## **EyePoint Pharmaceuticals to Present at the Jefferies Healthcare Conference**

May 31, 2023

WATERTOWN, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that George Elston, Chief Financial Officer of EyePoint Pharmaceuticals, will present a company overview at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 2:30 p.m. ET.

A live webcast and subsequent archived replay of the presentation may be accessed via the Investors section of the Company website at <a href="https://www.eyepointpharma.com">www.eyepointpharma.com</a>. The replay will be available for 90 days after the event.

## **About EyePoint Pharmaceuticals**

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary erodible Durasert E<sup>™</sup> technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment currently in Phase 2 clinical trials. The proven Durasert® drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA approved products. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. For more information visit <a href="https://www.eyepointpharma.com">www.eyepointpharma.com</a>.

## Investors:

Christina Tartaglia Stern IR Direct: 212-698-8700 christina.tartaglia@sternir.com

## **Media Contact**

Amy Phillips Green Room Communications Direct: 412-327-9499 aphillips@greenroompr.com



Source: EyePoint Pharmaceuticals, Inc.